Business Wire

MORGAN-STANLEY/CALVERT

Share
Morgan Stanley Investment Management Launches ESG Strategies Across Europe Managed by Calvert Research and Management

Calvert Research and Management (Calvert), a subsidiary of Morgan Stanley Investment Management, today announced the European launch of a suite of responsible investing strategies focused on Environmental, Social and Governance (ESG) factors. The new Calvert strategies meet the SFDR Article 9 criteria and have a sustainable investment objective across the ESG spectrum. This news follows MSIM’s acquisition of Eaton Vance, Calvert’s parent company in March, 2021.

Calvert, a recognized pioneer and leader in responsible investing since 1982, employs proprietary fundamental research, financially material ESG data analysis and direct company engagement to deliver competitive investment results across asset classes. The newly available strategies form a robust suite of offerings that invest in companies with leading ESG characteristics with the core objective of long-term value creation and positive global impact.

The Calvert Article 9 Funds are available through Morgan Stanley Investment Management’s distribution network and include the following:

  • MSINVF Calvert Sustainable Developed Europe Equity Select Fund
  • MSINVF Calvert Sustainable Developed Markets Equity Select Fund
  • MSINVF Calvert Sustainable Emerging Markets Equity Select Fund *
  • MSINVF Calvert Sustainable US Equity Select Fund
  • MSINVF Calvert Sustainable Diversity, Equity and Inclusion Fund
  • MSINVF Calvert Sustainable Climate Aligned Fund

“We are excited about leveraging Morgan Stanley Investment Management’s leading non-U.S. distribution capabilities to bring Calvert’s proven, Principles-based sustainable investment strategies to a much broader universe of investors,” said John Streur, President and Chief Executive Officer of Calvert Research and Management. “Our proprietary research system drives our investment process and enables us to identify the companies leading their peers in managing financially material ESG risks and opportunities, and those that are positioned for longer-term success and improved societal outcomes.”

Promoting environmental sustainability and resource efficiency, advocating for equitable societies and enhanced societal outcomes as well as demanding accountable governance and transparent operations are the core of the Calvert Principles for Responsible Investment, which form the foundation of Calvert’s investment process.

Calvert is a signatory to, and has played a leading role in spearheading, a number of global initiatives such as the United Nations Environment Programme Finance Initiative’s Principles of Responsible Investing (PRI), the Women’s Empowerment Principles and the UN Global Compact. Calvert also partners extensively with leading academic institutions and other ESG-oriented organizations to promote industry leading collaborative research.

“The combination of our research and engagement processes plus our work to support global change initiatives position us to offer impact-driven, responsible investing strategies that deliver long-term shareholder value and drive positive change,” added Mr. Streur.

“We are delighted to be able to bring Calvert’s historic understanding of ESG analysis, knowledge of responsible investing and success in long-term value creation to our European clients,” said Jacques Chappuis, Global Head of Distribution and Co-Head of the Solutions and Multi-Asset Group at Morgan Stanley Investment Management.. “Investors are increasingly focused on sustainability, and the launch of these new funds demonstrates our focus on delivering our clients best-in-class and market-leading products and solutions that align investor values with financial outcomes. European investors have a sophisticated understanding of how sustainability factors can lead to business success and Calvert has been honing this process for 40 years.”

* This fund is approved and will be available in the coming weeks

About Calvert Research and Management

Calvert Research and Management is a global leader in responsible investing. Calvert sponsors one of the largest and most diversified families of responsibly invested mutual funds, encompassing active and passively managed equity, income, alternative and multi-asset strategies, with approximately $37.3 billion in assets under management as of March 31, 2022.

With roots in responsible investing dating back to the 1982 launch of the first mutual fund to oppose investing in companies doing business in apartheid-era South Africa, the firm seeks to generate favourable investment returns for clients by allocating capital consistent with environmental, social and governance best practices and through structured engagement with portfolio companies. Headquartered in Washington, D.C., Calvert manages assets on behalf of funds, individual and institutional separate account clients, and their advisors. Calvert Research and Management is a wholly owned subsidiary of Morgan Stanley Investment Management.

About Morgan Stanley Investment Management

Morgan Stanley Investment Management, together with its investment advisory affiliates, has more than 767 investment professionals around the world and $1.4 trillion in assets under management or supervision as of March 31, 2022. Morgan Stanley Investment Management strives to provide outstanding long-term investment performance, service and a comprehensive suite of investment management solutions to a diverse client base, which includes governments, institutions, corporations and individuals worldwide. For further information about Morgan Stanley Investment Management, please visit www.morganstanley.com/im .

About Morgan Stanley

Morgan Stanley (NYSE: MS) is a leading global financial services firm providing a wide range of investment banking, securities, wealth management and investment management services. With offices in 41 countries, the Firm's employees serve clients worldwide including corporations, governments, institutions and individuals. For more information about Morgan Stanley, please visit www.morganstanley.com .

Disclaimer:

FMIL

This marketing communication has been issued by Morgan Stanley Investment Management Fund Management (Ireland) Limited. Morgan Stanley Investment Management Fund Management (Ireland) Limited is regulated by the Central Bank of Ireland. Morgan Stanley Investment Management Fund Management (Ireland) Limited is incorporated in Ireland as a private company limited by shares with company registration number 616661 and has its registered address at The Observatory, 7-11 Sir John Rogerson's Quay, Dublin 2, D02 VC42, Ireland.

MSINVF CBDF

This is a marketing communication. Applications for shares in the Fund should not be made without first consulting the current Prospectus and the Key Investor Information Document (“KIID”), which are available in English and in the official language of your local jurisdiction at morganstanleyinvestmentfunds.com or free of charge from the Registered Office of Morgan Stanley Investment Funds, European Bank and Business Centre, 6B route de Trèves, L-2633 Senningerberg, R.C.S. Luxemburg B 29 192. A summary of investor rights is available in English at the same website.

If the management company of the relevant Fund decides to terminate its arrangement for marketing that Fund in any EEA country where it is registered for sale, it will do so in accordance with the relevant UCITS rules.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Brenus Pharma Reports Favorable Tolerability and Clinical Signals in Early Preliminary Results of First-In-Human Study for STC-1010 in Unresectable Metastatic Stage Colorectal Cancer (MSS CRC) Patients6.1.2026 21:00:00 CET | Press release

Brenus Pharma, a clinical stage biotechnology company unlocking the immune system in vivo to fight solid tumors, announced the successful completion of the first dose levels in its ongoing first-in-human study. The multi-center, open-label trial (NCT06934538) is a phase Ia/Ib study designed to evaluate safety, tolerability and preliminary clinical activity of STC-10101 in a first line setting. It will include in vivo analysis of immune and tumor dynamics during dose escalation of treatment and cohort extension to patients with unresectable locally advanced (stage IIIC, T4b) or unresectable metastatic (stage IV) MSS2 colorectal cancer (CRC). Early findings indicate that the first dose levels have been successfully completed with good overall tolerance and no-dose-limiting toxicities observed to date. “We are pleased to report that the safety profile observed to date is good and consistent with our expectations with no DLT,” said Paul Bravetti, CEO of Brenus Pharma. “Moreover, preliminar

SPIE, the International Society for Optics and Photonics, Announces Its 2026 Fellows6.1.2026 20:35:00 CET | Press release

The Society is welcoming 40 new Fellow Members from across the globe SPIE, the international society for optics and photonics, welcomes 40 Members as new Fellows of the Society in the 2026 cohort. They join their Fellow Member colleagues in being honored for their excellent technical achievements, as well as for their substantial service to the optics and photonics community and to SPIE. Fellows are Members of the Society who have made significant scientific and technical contributions in the multidisciplinary fields of optics, photonics, and imaging. Since the Society's inception in 1955, more than 1,800 SPIE Members have become Fellows. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260106630672/en/ SPIE, the international society for optics and photonics, announces its 2026 Fellows This year’s inductees are high-profile leaders in academia, industry, and government, many of whom are particularly prominent in their support

Chemelex Adds Electric Heat Trace Group Ltd.’s SmartTrace Monitoring Platform to its Heat Tracing Portfolio6.1.2026 20:00:00 CET | Press release

Chemelex, a global leader in electric thermal and sensing solutions, today announced the successful completion of its acquisition of substantially all the assets and ongoing operations of Electric Heat Trace Group Ltd. (EHT Group), headquartered in Ontario, Canada. This strategic move marks an exciting start to the new year and reinforces Chemelex’s commitment to delivering smarter, data-driven solutions for industrial heat trace systems. EHT Group is a recognized innovator in heat trace management, offering advanced software, integrated controller solutions, wireless communication modules, and comprehensive field services. Its flagship platform, SmartTrace, is a robust solution available in both cloud-based and on-premises deployments that enables predictive maintenance, minimizes downtime, and provides secure remote monitoring—helping customers achieve greater reliability and operational efficiency. This endeavor will help Chemelex support greater operational efficiencies for our cus

ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA6.1.2026 19:30:00 CET | Press release

Combination therapy showed compelling survival and disease control compared to current standard, regardless of PD-L1 statusHigh GEA burden in Asia, where BeOne holds ZIIHERA rights, signals potential broad patient impactResults to be presented as a Late-Breaking Abstract Oral Presentation at ASCO GI on January 8, 2026 BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced full results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with and without PD-1 inhibitor TEVIMBRA® (tislelizumab), as a first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). These data, including the first interim overall survival (OS) analysis, will be presented as a Late-Breaking Abstract Oral Presentation (#LBA285) at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) on

Siemens and NVIDIA Expand Partnership to Build the Industrial AI Operating System6.1.2026 18:07:00 CET | Press release

Through AI, Siemens and NVIDIA are reinventing the entire end-to-end industrial value chain – from design and engineering to manufacturing, production, operations, and into supply chainsSiemens and NVIDIA to build AI-accelerated portfolio including AI-native electronic design, AI native simulation as well as AI driven adaptive manufacturing and supply chainSiemens and NVIDIA to design the next generation of AI factoriesSiemens and NVIDIA to optimize operations through shared innovation CES 2026 - Siemens and NVIDIA today announced a significant expansion of their strategic partnership to bring artificial intelligence into the real world. Together, the companies aim to develop industrial and physical AI solutions that will bring AI-driven innovation to every industry and industrial workflow, as well as accelerate each others’ operations. To support development, NVIDIA will provide AI infrastructure, simulation libraries, models, frameworks and blueprints, while Siemens will commit hundr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye